Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

5-Aza-4′-thio-2′-deoxycytidine, a New Orally Bioavailable Nontoxic “Best-in-Class”: DNA Methyltransferase 1–Depleting Agent in Clinical Development

9 Sept 2021

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Epigenetics and DNA Methylation
Share to Hemoglobinopathies and Related Disorders

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34503994
DOI: 10.1124/jpet.121.000758

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

5-Aza-4′-thio-2′-deoxycytidine, a New Orally Bioavailable Nontoxic “Best-in-Class”: DNA Methyltransferase 1–Depleting Agent in Clinical DevelopmentPMID 34503994Read ↗

Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinicSemantic proximity Read ↗

DNA Methylation–Targeted DrugsSemantic proximity Read ↗

DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studiesSemantic proximity Read ↗

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read ↗

Combination therapy with DNA methyltransferase inhibitors in hematologic malignanciesSemantic proximity Read ↗

Investigating the safety and efficacy of deoxycytidine/deoxythymidine in mitochondrial DNA depletion disorders: phase 2 open-label trialSemantic proximity Read ↗

A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumorsSemantic proximity Read ↗

Harmine, a Novel DNA Methyltransferase 1 Inhibitor in the Leukemia Cell LineSemantic proximity Read ↗

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenograftsSemantic proximity Read ↗

DNA Methyltransferase Inhibitors and their Therapeutic PotentialSemantic proximity Read ↗

Clinical development of demethylating agents in hematologySemantic proximity Read ↗

Novel prodrugs of decitabine with greater metabolic stability and less toxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.